Benzinga's Top Downgrades

Analysts at Jefferies & Company downgraded Halozyme Therapeutics Inc

from “buy” to “hold.” HALO's shares closed at $12.15 yesterday. Halozyme Therapeutics' trailing-twelve-month ROE is -126.52%. Analysts at JP Morgan downgraded Jacobs Engineering Group Inc

from “overweight” to “neutral.” JEC's shares closed at $43.02 yesterday. Jacobs Engineering's trailing-twelve-month profit margin is 3.33%. Brean Murray Carret & Co downgraded Allos Therapeutics Inc

from “buy” to “hold.” ALTH's shares closed at $1.81 yesterday. Allos Therapeutics' trailing-twelve-month ROA is -15.47%. Guggenheim downgraded Bryn Mawr Bank Corp

from “buy” to “neutral.” BMTC's shares closed at $21.10 yesterday. Bryn Mawr Bank's trailing-twelve-month revenue is $90.84 million.